Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six Months-Reference-Cited by-同舟云学术

Molnupiravir Treatment for COVID-19 in People at Higher Risk in the Community: Outcomes from the PANORAMIC Randomised Controlled Trial at Three and Six Months

Published:2024 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Harris Victoria,Holmes Jane,Gbinigie Oghenekome,Rahman Najib M.,Richards Duncan,Hayward Gail,Dorward Jienchi,Lowe David,Standing Joseph,Breuer Judith,Khoo Saye,Petrou Stavros,Hood Kerenza,Ahmed Haroon,Carson-Stevens Andrew,Nguyen-Van-Tam Jonathan,Patel Mahendra,Saville Benjamin,Francis Nick,Thomas Nicholas BP,Evans Philip,Dobson Melissa,Png May Ee,Lown Mark,van Hecke Oliver,Jani Bhautesh,Hart Nigel,Butler Daniel,Cureton Lucy,Patil Meena,Andersson Monique,Coates Maria,Williams Sarah,Bateman Clare,Davies Jennifer,Raymundo-Wood Ivy,Ustianowski Andrew,Yu Ly-Mee,Hobbs F.D. Richard,Little Paul,Butler Christopher,Group PANORAMIC Trial Collaborative

Publisher

Elsevier BV

Reference13 articles.

1. Long COVID: the next public health crisis is already on its way;C Yang;Lancet Reg Health Eur,2023

2. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 30 March 2023. released;ONS website, statistical bulletin,2023

3. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials;Y Gao;Clin Microbiol Infect,2023

4. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19;J Hammond;N Engl J Med,2022

5. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an openlabel, platform-adaptive randomised controlled trial;C C Butler;Lancet,2023